Lumos Diagnostics (ASX: LDX): Enters Its Proof Phase as LDX Breaks the Downtrend
Jul 22, 2026
Proactive Equities Team
Lumos Diagnostics continues to expand its commercial footprint through FDA clearance, growing U.S. adoption, manufacturing partnerships, and paediatric research. The company now focuses on turning regulatory success and market access into recurring sales, broader reimbursement, and sustainable long-term growth.